Arcturus Therapeutics Holdings (ARCT) EBIAT (2018 - 2025)
Historic EBIAT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$13.4 million.
- Arcturus Therapeutics Holdings' EBIAT fell 9481.38% to -$13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.7 million, marking a year-over-year decrease of 649.07%. This contributed to the annual value of -$80.9 million for FY2024, which is 17229.94% down from last year.
- Arcturus Therapeutics Holdings' EBIAT amounted to -$13.4 million in Q3 2025, which was down 9481.38% from -$9.2 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' 5-year EBIAT high stood at $117.3 million for Q4 2022, and its period low was -$56.3 million during Q1 2021.
- Moreover, its 5-year median value for EBIAT was -$21.6 million (2022), whereas its average is -$18.0 million.
- Per our database at Business Quant, Arcturus Therapeutics Holdings' EBIAT plummeted by 47631.18% in 2021 and then skyrocketed by 40351.24% in 2022.
- Arcturus Therapeutics Holdings' EBIAT (Quarter) stood at -$38.7 million in 2021, then surged by 403.51% to $117.3 million in 2022, then crashed by 109.98% to -$11.7 million in 2023, then plummeted by 156.3% to -$30.0 million in 2024, then surged by 55.18% to -$13.4 million in 2025.
- Its last three reported values are -$13.4 million in Q3 2025, -$9.2 million for Q2 2025, and -$14.1 million during Q1 2025.